Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Commentary|Articles|October 17, 2025
AJMC® in the Press, October 17, 2025
Author(s)Julia Bonavitacola
Fact checked by: Christina Mattina
Listen
0:00 / 0:00
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
An item from
Advertisement
Related to this article
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Tavapadon for Parkinson Disease Approved by FDA
3
Health System Pharmacies Keep Patients on GLP-1 Therapy
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5